Gilead Sciences, Inc. $GILD Stock Holdings Increased by Commonwealth of Pennsylvania Public School Empls Retrmt SYS

Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.0% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 305,081 shares of the biopharmaceutical company’s stock after acquiring an additional 20,076 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Gilead Sciences were worth $33,824,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Foundations Investment Advisors LLC lifted its position in shares of Gilead Sciences by 26.4% in the 2nd quarter. Foundations Investment Advisors LLC now owns 82,876 shares of the biopharmaceutical company’s stock valued at $9,188,000 after acquiring an additional 17,318 shares in the last quarter. Wrapmanager Inc. increased its position in Gilead Sciences by 32.0% in the 2nd quarter. Wrapmanager Inc. now owns 9,300 shares of the biopharmaceutical company’s stock worth $1,031,000 after purchasing an additional 2,254 shares during the last quarter. Banco Bilbao Vizcaya Argentaria S.A. increased its holdings in Gilead Sciences by 0.3% in the second quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 566,262 shares of the biopharmaceutical company’s stock worth $62,771,000 after buying an additional 1,729 shares during the last quarter. Clearstead Trust LLC increased its stake in shares of Gilead Sciences by 116.2% during the 2nd quarter. Clearstead Trust LLC now owns 813 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 437 shares during the last quarter. Finally, Credit Capital Investments LLC bought a new position in Gilead Sciences during the second quarter valued at about $255,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on GILD. Needham & Company LLC increased their price target on Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a report on Thursday. BMO Capital Markets upped their price target on Gilead Sciences from $130.00 to $135.00 and gave the company an “outperform” rating in a report on Monday, October 20th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. UBS Group boosted their price target on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research note on Friday, August 8th. Finally, Wells Fargo & Company boosted their price target on shares of Gilead Sciences from $140.00 to $145.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $129.13.

Insiders Place Their Bets

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total value of $1,193,900.00. Following the sale, the chief executive officer directly owned 581,203 shares of the company’s stock, valued at approximately $69,389,826.17. The trade was a 1.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $354,240.00. Following the transaction, the insider directly owned 110,193 shares of the company’s stock, valued at $13,011,589.44. This represents a 2.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 94,646 shares of company stock worth $11,311,286. 0.27% of the stock is owned by company insiders.

Gilead Sciences Price Performance

GILD opened at $125.02 on Friday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a 52 week low of $86.08 and a 52 week high of $127.68. The company has a fifty day moving average price of $117.44 and a two-hundred day moving average price of $112.83. The firm has a market capitalization of $155.11 billion, a PE ratio of 24.90, a P/E/G ratio of 0.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be given a $0.79 dividend. The ex-dividend date is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio is currently 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.